BR9708706A - Composição farmacêutica para administração intravenosa a um paciente e processo para produzir a mesma para tratar e/ou prevenir infecções fúngicas em um mamífero e para tratar um infecção causada por candida sp aspergillus sp e pneumocystis carinii - Google Patents

Composição farmacêutica para administração intravenosa a um paciente e processo para produzir a mesma para tratar e/ou prevenir infecções fúngicas em um mamífero e para tratar um infecção causada por candida sp aspergillus sp e pneumocystis carinii

Info

Publication number
BR9708706A
BR9708706A BR9708706A BR9708706A BR9708706A BR 9708706 A BR9708706 A BR 9708706A BR 9708706 A BR9708706 A BR 9708706A BR 9708706 A BR9708706 A BR 9708706A BR 9708706 A BR9708706 A BR 9708706A
Authority
BR
Brazil
Prior art keywords
treat
candida
aspergillus
mammal
patient
Prior art date
Application number
BR9708706A
Other languages
English (en)
Other versions
BR9708706B8 (pt
BR9708706B1 (pt
Inventor
Maneesh J Nerurkar
William A Hunke
Michael J Kaufman
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9708706(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9611006.9A external-priority patent/GB9611006D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9708706A publication Critical patent/BR9708706A/pt
Publication of BR9708706B1 publication Critical patent/BR9708706B1/pt
Publication of BR9708706B8 publication Critical patent/BR9708706B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
BRPI9708706A 1996-04-19 1997-04-15 composição farmacêutica para administração intravenosa a um paciente BR9708706B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1563896P 1996-04-19 1996-04-19
GBGB9611006.9A GB9611006D0 (en) 1996-05-24 1996-05-24 Antifungal compositions
PCT/US1997/006284 WO1997039763A1 (en) 1996-04-19 1997-04-15 Compositions comprising antifungal agent and acetate buffer

Publications (3)

Publication Number Publication Date
BR9708706A true BR9708706A (pt) 1999-08-03
BR9708706B1 BR9708706B1 (pt) 2013-08-06
BR9708706B8 BR9708706B8 (pt) 2019-03-06

Family

ID=26309400

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9708706A BR9708706B8 (pt) 1996-04-19 1997-04-15 composição farmacêutica para administração intravenosa a um paciente
BRPI9708706A BRPI9708706C8 (pt) 1996-04-19 1997-04-15 composição farmacêutica para administração intravenosa a um paciente

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9708706A BRPI9708706C8 (pt) 1996-04-19 1997-04-15 composição farmacêutica para administração intravenosa a um paciente

Country Status (35)

Country Link
EP (1) EP0904098B1 (pt)
JP (1) JP3258672B2 (pt)
CN (1) CN1132624C (pt)
AR (1) AR006598A1 (pt)
AT (1) ATE241999T1 (pt)
AU (1) AU706250B2 (pt)
BG (1) BG64272B1 (pt)
BR (2) BR9708706B8 (pt)
CA (1) CA2251928C (pt)
CO (1) CO4940486A1 (pt)
CY (1) CY2374B1 (pt)
CZ (1) CZ289361B6 (pt)
DE (1) DE69722615T2 (pt)
DK (1) DK0904098T3 (pt)
DZ (1) DZ2205A1 (pt)
EA (1) EA001386B1 (pt)
EE (1) EE04265B1 (pt)
ES (1) ES2198569T3 (pt)
HR (1) HRP970201B1 (pt)
HU (1) HU228296B1 (pt)
ID (1) ID16643A (pt)
IL (1) IL126479A (pt)
IS (1) IS2159B (pt)
MY (1) MY126305A (pt)
NO (1) NO321954B1 (pt)
NZ (1) NZ332156A (pt)
PE (1) PE63998A1 (pt)
PL (1) PL187294B1 (pt)
PT (1) PT904098E (pt)
RS (1) RS49566B (pt)
SA (1) SA97180104B1 (pt)
SK (1) SK281969B6 (pt)
TR (1) TR199802102T2 (pt)
UA (1) UA55409C2 (pt)
WO (1) WO1997039763A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970318B1 (en) 1996-06-14 2002-06-30 Merck & Co Inc A process for preparing certain aza cyclohexapeptides
HK1040062A1 (zh) * 1999-03-03 2002-05-24 Eli Lilly And Company 含有成胶束表面活性剂的棘白菌素药物配方
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
CN101516387B (zh) * 2006-07-26 2014-06-04 桑多斯股份公司 卡泊芬净制剂
JP5373606B2 (ja) * 2006-07-26 2013-12-18 サンド・アクチエンゲゼルシヤフト カスポファンギン製剤
WO2009002481A1 (en) 2007-06-26 2008-12-31 Merck & Co., Inc. Lyophilized anti-fungal composition
US8048853B2 (en) 2008-06-13 2011-11-01 Xellia Pharmaceuticals Aps Process for preparing pharmaceutical compound and intermediates thereof
US20100256074A1 (en) * 2008-06-25 2010-10-07 Chaim Eidelman Processes for preparing high purity aza cyclohexapeptides
WO2010108637A1 (en) * 2009-03-27 2010-09-30 Axellia Pharmaceuticals Aps Crystalline compound
CN102219832B (zh) * 2010-04-15 2013-08-21 上海天伟生物制药有限公司 一种氮杂环六肽或其盐的纯化方法
CN102367267B (zh) * 2010-11-10 2013-09-04 上海天伟生物制药有限公司 一种卡泊芬净的制备方法
CN102367268B (zh) * 2010-11-10 2013-11-06 上海天伟生物制药有限公司 一种卡泊芬净类似物及其用途
CN102367269B (zh) * 2010-11-10 2013-11-06 上海天伟生物制药有限公司 一种卡泊芬净类似物及其制备方法和用途
CN102488888B (zh) * 2011-01-31 2014-07-30 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂的药用组合物及其制备方法和用途
CN102488887B (zh) * 2011-01-31 2014-06-18 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂卡泊芬净的药用组合物及其制备方法和用途
CN102614493B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂卡泊芬净的液体药用组合物
WO2012119065A2 (en) 2011-03-03 2012-09-07 Seachaid Pharmaceuticals, Inc. Antifungal agents and uses thereof
CN102166186A (zh) * 2011-04-18 2011-08-31 深圳市健元医药科技有限公司 一种更加稳定的氮杂环己肽类制剂
CN103315969B (zh) * 2011-09-26 2016-05-18 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
CN102488889B (zh) * 2011-09-26 2014-01-22 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
CN103212059A (zh) * 2012-01-18 2013-07-24 江苏恒瑞医药股份有限公司 含有抗真菌药物和乳酸盐缓冲液的组合物
SI3677252T1 (sl) * 2012-03-19 2024-02-29 Cidara Therapeutics, Inc. Sheme odmerjanja za spojine iz razreda ehinokandinov
HK1222185A1 (zh) 2013-05-02 2017-06-23 中化帝斯曼制药有限公司荷兰公司 分离卡泊芬净的方法
PL3058958T3 (pl) 2015-02-23 2019-02-28 Selectchemie Ag Kompozycja anidulafunginy
MA43825A (fr) 2016-03-16 2021-04-07 Cidara Therapeutics Inc Schémas posologiques pour le traitement d'infections fongiques
JP7779651B2 (ja) 2017-07-12 2025-12-03 ナップ ファーマシューティカル グループ リミテッド 真菌感染症の処置のための組成物及び方法
CN109721641B (zh) * 2017-10-31 2021-08-03 鲁南制药集团股份有限公司 一种卡泊芬净的合成方法
CN113801202B (zh) * 2020-06-15 2024-11-05 杭州中美华东制药有限公司 一种醋酸卡泊芬净杂质g的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
WO1989011297A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
US5939384A (en) * 1991-10-01 1999-08-17 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US5378804A (en) * 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid compositions of gamma interferon

Also Published As

Publication number Publication date
DE69722615D1 (de) 2003-07-10
JPH11509555A (ja) 1999-08-24
PE63998A1 (es) 1998-10-30
CA2251928C (en) 2003-06-17
HRP970201A2 (en) 1998-08-31
AU706250B2 (en) 1999-06-10
HUP9901586A3 (en) 2002-05-28
CZ334798A3 (cs) 1999-06-16
ES2198569T3 (es) 2004-02-01
RS49566B (sr) 2007-04-10
HU228296B1 (en) 2013-03-28
IS4858A (is) 1998-10-02
DK0904098T3 (da) 2003-09-15
YU45098A (sh) 1999-07-28
PL187294B1 (pl) 2004-06-30
EE04265B1 (et) 2004-04-15
BRPI9708706C8 (pt) 2021-01-05
HUP9901586A2 (hu) 1999-08-30
MY126305A (en) 2006-09-29
CY2374B1 (en) 2004-06-04
ATE241999T1 (de) 2003-06-15
AR006598A1 (es) 1999-09-08
NO984860L (no) 1998-12-18
EP0904098B1 (en) 2003-06-04
EE9800345A (et) 1999-04-15
WO1997039763A1 (en) 1997-10-30
NO984860D0 (no) 1998-10-16
HRP970201B1 (en) 2002-06-30
BG64272B1 (bg) 2004-08-31
PT904098E (pt) 2003-09-30
EA199800938A1 (ru) 1999-04-29
JP3258672B2 (ja) 2002-02-18
PL329442A1 (en) 1999-03-29
DZ2205A1 (fr) 2002-12-03
ID16643A (id) 1997-10-23
CN1132624C (zh) 2003-12-31
EA001386B1 (ru) 2001-02-26
HK1020873A1 (en) 2000-05-26
IS2159B (is) 2006-11-15
NO321954B1 (no) 2006-07-31
SK281969B6 (sk) 2001-09-11
CA2251928A1 (en) 1997-10-30
UA55409C2 (uk) 2003-04-15
SA97180104B1 (ar) 2006-02-08
AU2731197A (en) 1997-11-12
EP0904098A1 (en) 1999-03-31
IL126479A (en) 2006-08-01
CZ289361B6 (cs) 2002-01-16
NZ332156A (en) 2000-04-28
CN1222082A (zh) 1999-07-07
BR9708706B8 (pt) 2019-03-06
TR199802102T2 (xx) 1999-01-18
BR9708706B1 (pt) 2013-08-06
BG102857A (en) 1999-09-30
SK144898A3 (en) 1999-05-07
IL126479A0 (en) 1999-08-17
DE69722615T2 (de) 2004-04-29
CO4940486A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
BR9708706A (pt) Composição farmacêutica para administração intravenosa a um paciente e processo para produzir a mesma para tratar e/ou prevenir infecções fúngicas em um mamífero e para tratar um infecção causada por candida sp aspergillus sp e pneumocystis carinii
DE69214938D1 (de) Mittel zur topischen verabreichung von arzneiwirkstoffen
BR9609152A (pt) Processo para tratamento de infecção por hiv em um individuo inibição da replicação do hiv e composição farmaceutica aceitavel util para o tratamento de infecção por hiv
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
BR9508237A (pt) Composto derivado farmaceuticamente aceitável de um composto formulação farmacéutica uso de um composto método de tratamento ou prevenção dos sintomas ou efeitos de uma infecção por vírus em um animal infectado e processo para a preparação de um composto
BR9815264A (pt) Componentes de aumento de penetracao na pele
CA2309688A1 (en) Penetration enhancing and irritation reducing systems
BRPI0011640B8 (pt) ácidos aldônicos de oligossacarídeo e seu uso tópico
BR9510423A (pt) Formulação lipossomal multilamelar de baixa rigidez processo de tratamento ou de profilaxia de uma infecção bacteriana em um animal e de uma variante mucoìde da mesma, uso da formulação lipossomal antibacteriana
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR9206631A (pt) Sistema de maior penetração na pele para melhor administração tópica de medicamentos
SE9500209D0 (sv) Treatment of cerebral ischemia and cerebral damage with neuroprotective agent
ATE243029T1 (de) Transdermales system zur verabreichung durch entepithelisierte haut
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
DE69815122D1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
BR9807199A (pt) Composição oral e processo para o tratamento e a prevenção de acúmulo de placa bacteriana sobre dentes.
DK0538302T3 (da) Reduktion eller forhindring af hudirritation forårsaget af lægemidler
BR9507189A (pt) Combinaçoes de proteinas tromboliticamente ativas e anticoagulantes e usos dos mesmos
FI963883L (fi) Farmaseuttisia valmisteita ja lääkeaineita endoteelin toimintahäiriön ehkäisemiseksi ja hoitamiseksi
DE60036915D1 (de) Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
WO2001010387A3 (en) Antiviral therapy use of P-glycoprotein modulators
ATE77230T1 (de) Melatoninhaltige mittel sowie deren verwendungen.
BR0307211A (pt) Composições tópicas possuindo um ingrediente natural e método de utilização
KR960705578A (ko) 경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease)
SE9303612D0 (sv) New use

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: O EXAME NECESSAARIO DO PEDIDO DE PATENTE

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: NOME ALTERADO DE: MERCK AND CO., INC.

B15W Others matters related to applications: legal action concerning application

Free format text: INPI-52400.033511/2013-21 ORIGEM: JUIZO DA 08A VARA FEDERAL DE BRASILIA PROCESSO NO 21242-78.2013.4.01.3400 ACAO ORDINARIA DE NULIDADE DA DECISAO PROFERIDA PELA ANVISA QUE DENEGOU ANUENCIA PREVIA AO PEDIDO, COM PEDIDO DE TUTELA ANTECIPADA AUTOR: MERCK SHARP AND DOHME CORP. REU: AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA.

B15N Others concerning applications: notification of judicial decision

Free format text: INPI-52400.033511/13 TRIBUNAL REGIONAL FEDERAL DA 1A REGIAO - 008A VARA FEDERAL DE BRASILIA PROCESSO NO. 21242-78.2013.4.01.3400 AUTOR: MERCK SHARP DOHME CORP REU: AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA DECISAO: ANTE O EXPOSTO, DEFIRO A TUTELA DE URGENCIA PARA DETERMINAR A REMESSA IMEDIATA DO PEDIDO DE PATENTE PI 9708706-8 AO INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL, BEM COMO O IMEDIATO PROSSEGUIMENTO DO PROCESSO DE CONCESSAO DE PATENTES.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2013, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B25D Requested change of name of applicant approved
B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061601/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132345-04.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: MERIAL, SCHERING CORPORATION, FLAMEL TECHNOLOGIES E WARNER-LAMBERT COMPANY LLC

B25G Requested change of headquarter approved
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTES DA NULIDADE: 1O) CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA. 2O) EUROFARMA LABORATORIOS S.A.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.109667/2017-14 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO 31A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO 0503013-53.2015.4.02.5101 AUTOR: MERCK SHARP AND DOHME CORPORATION REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI DECISAO: PELO EXPOSTO, DEFIRO O REQUERIMENTO FORMULADO PELO INPI, DETERMINANDO A IMEDIATA CORRECAO DO PRAZO DE VIGENCIA DA PATENTE PI9708706-8 PARA 15.04.2017.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/04/1997, OBSERVADAS AS CONDICOES LEGAIS. (CO) REF.RPI 2222 DE 06/08/2013 QUANTO AO PRAZO DE VALIDADE, ALTERADO CONFORME INPI NO 52400.109667/2017-14 - TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO - 31A VARA FEDERAL DO RIO DE JANEIRO - PROCESSO NO 0503013-53.2015.4.02.5101 PARA 15/04/2017.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI NO 52400.109667/2017-14 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO 31A VARA FEDERAL DO RIO DE JANEIRO OFICIO NO OFI.8200.000552-6/2020-SUB2T-ESP PROCESSO JUDICIAL: 0503013-53.2015.4.02.5101 IMPETRANTE: MERCK SHARP AND DOHME CORPORATION IMPETRADO: INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIAL - INPI DECISAO: DEFIRO OS REQUERIMENTOS FORMULADOS PELA MERCK SHARP AND DOHME CORPORATION EM FL. 2062 E DETERMINO A EXPEDICAO DE OFICIO PARA QUE O INPI PUBLIQUE (I) O DESPACHO 19.1, REFERENTE A "NOTIFICACAO DECISAO JUDICIAL DETERMINANDO QUE SEJA MANTIDO O PRAZO DE VIGENCIA DA PATENTE PI9708706-8 TAL COMO ORIGINALMENTE CONCEDIDO (06/08/2023)"; E (II) O DESPACHO 16.3, REFERENTE A "RETIFICAC

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2222 DE 06/08/2013 QUANTO AO PRAZO DE VIGENCIA, CONFORME DETERMINADO NO INPI NO 52400.109667/2017-14 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO 31A VARA FEDERAL DO RIO DE JANEIRO OFICIO NO OFI.8200.000552-6/2020-SUB2T-ESP PROCESSO JUDICIAL: 0503013-53.2015.4.02.5101 IMPETRANTE: MERCK SHARP AND DOHME CORPORATIONIMPETRADO: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/04/1997, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.